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Abstract  
Context: Patients with Addison‟s disease (AD) self-report impairment in specific dimensions on well-
being questionnaires. An AD disease-specific quality-of-life questionnaire (AddiQoL) was developed 
to aid evaluation of patients.  
Objective: We aimed to translate and determine construct validity, reliability, and concurrent validity 
of the AddiQoL questionnaire. 
Methods: After translation, the final versions were tested in AD patients from Norway (n=107), 
Sweden (n=101), Italy (n=165), Germany (n=200) and Poland (n=50). Construct validity was 
examined by exploratory factor analysis (EFA) and Rasch analysis, aiming at unidimensionality and 
fit to the Rasch model. Reliability was determined by Cronbach‟s α and Person Separation Index 
(PSI). Longitudinal reliability was tested by Differential Item Functioning (DIF) in stable patient 
subgroups. Concurrent validity was examined in Norwegian (n=101) and Swedish (n=107) patients. 
Results: EFA and Rasch analysis identified six items with poor psychometric properties. The 30 
remaining items fitted the Rasch model and proved unidimensional; supported by appropriate item and 
person fit residuals and a non-significant Chi-Square probability. Crohnbach‟s α 0.93 and PSI 0.86 
indicates high reliability. Longitudinal reliability was excellent. Correlation with SF-36 and PGWB 
scores were high. A shorter Fatigue subscale comprising eight items also proved valid and reliable. 
Testing of AddiQoL-30 in this large patient cohort showed significantly worse scores with increasing 
age, and in women compared with men, but no difference between patients with isolated AD and those 
with concomitant diseases.  
Conclusion: The validation process concluded with a revised 30-item AddiQoL questionnaire and a 
Fatigue subscale with good psychometric properties and high reliability. 
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Primary adrenal insufficiency (Addison‟s disease, AD) is a rare chronic disease treated with 
glucocorticoid and mineralocorticoid replacement (1), and additional replacement of the adrenal 
androgen dehydroepiandrosterone (DHEA) is debated (2-5). Novel treatment strategies such as 
modified-release hydrocortisone tablets or continuous subcutaneous hydrocortisone infusion are under 
investigation (6-9). There is no „gold-standard‟ for assessment of treatment, but a clinical scoring 
system has been proposed (10). Patient surveys reproducibly report impairment in particular 
dimensions of general well being questionnaires (3, 11, 12). Generic questionnaires have been applied 
to study differences between subgroups of patients with AD (13, 14) and other autoimmune 
endocrinopathies (15). However, questionnaires containing disease-specific items are likely to be more 
sensitive to effects that clinicians wish to monitor (16).  Recently, The AddiQoL 36-item disease-
specific questionnaire was developed as an evaluative disease-specific questionnaire in AD (17), 
which might facilitate the detection of changes in well-being in future clinical trials and during regular 
follow-up of the patients. 
 
Validity is the process of demonstrating that an instrument measures what it intends to measure, and 
that it is useful for this purpose. Construct validity aligns a questionnaire to a theorized underlying 
trait, and involves testing of correlation between the items. Here, we used Rasch analysis to explore 
the psychometric properties of AddiQoL. Rasch analysis is a mathematical item response model 
increasingly used in somatic medicine and endocrinology, such as validation of QoL-AGHDA, 
AcroQoL and CushingQoL (18-20). The objective is to test how well the observed data fit to the 
expectations of the mathematic measurement model (21, 22).  
 
Reliability implies the degree to which an instrument is free from random error. The traditional 
reliability coefficient (Cronbach‟s α) indicates how well an individual item correlates with the other 
items in a questionnaire. In Rasch analysis, the Person Separation index (PSI) is equivalent to 
Crohnbach‟s α, and represents the power of the construct to discriminate between respondents, giving 
an indication of how precisely patients have been spread out along the continuum (23). Test-retest 
reliability or repeatability is the correlation between scores obtained by the same persons on two 
separate occasions given that their clinical condition is stable.  
 
Concurrent validity concerns how the questionnaire performs against some “gold standard” 
instrument, usually by exploring correlation of questionnaire scores. The AddiQoL is to our 
knowledge the first disease-specific HRQoL questionnaire in AD, therefore no such “gold standard” 
exist. In endocrinology, the SF-36 (Short-Form-36 ) and the PGWB (Psychological General Well-
Being Index) have been included in the validation of AGHDA (24, 25), AcroQoL (26) and 
CushingQoL (20). 
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Validation of a questionnaire requires responses from a number of subjects, which is difficult to obtain 
within one country for a rare disease such as AD. Hence, in the current study we translated the original 
English AddiQoL into Norwegian, Swedish, Italian, German and Polish versions; these were 
administered to large cohorts of patients with AD in each country for evaluation of construct validity 
and reliability. Test-retest reliability was tested in patient subgroups in Norway, Italy and Sweden. 
Concurrent validity was investigated by examining correlation between the AddiQoL scores and 
simultaneously obtained results from SF-36 and PGWB questionnaires in Norway and Sweden. We 
also sampled AddiQoL data from a random population sample in Norway. The final questionnaire was 
ultimately used to assess HRQoL in different subgroups of this large cohort.  
 
Methods 
 
Design and subjects 
First, the AddiQoL was translated from English into Norwegian, Swedish, German, Polish and Italian 
versions, following international recommendations (27). Second, patients with verified AD were 
recruited from patient registries, or consecutively from outpatient clinics. The patients received an 
inviting letter containing study information and the AddiQoL; by returning the anonymized 
questionnaires they were included in the study. Patients in Norway and Sweden in addition received 
the SF-36 and the PGWB for analysis of concurrent validity. There were no exclusion criteria. Patient 
characteristics such as age, sex and concurrent autoimmune diseases were retrieved from the registries 
or through an additional questionnaire. For analysis of longitudinal reliability a subgroup of at least 20 
patients from Norway, Sweden and Italy received a second AddiQoL 2-6 weeks after the first. For 
normative data, a random sample from the Norwegian population received an inviting letter containing 
study information and the AddiQoL; by returning the anonymized questionnaires they were included. 
Third, the responses from the patients were analyzed by exploratory factor analysis (EFA) and Rasch 
analysis for assessment of validity and reliability, and hence for amendment of the questionnaire. The 
study was approved by the Regional Ethics committees in each country. 
 
Translation 
The forward translation was performed by a minimum of three native speakers of the target language, 
who had good knowledge of English. Translations were performed locally by the study group in each 
country. Their preliminary versions were discussed locally by a panel of experts, i.e. clinicians in 
endocrinology, agreeing upon versions to be evaluated further. For quality control, these versions were 
assessed by two professional translators (Lionbridge Technologies Inc.), native speakers of the target 
language, who evaluated the conceptual equivalence with the original, clarity and use of a familiar 
register. Thus, two adjusted versions of each AddiQoL translation were generated, which were re-
evaluated by the study groups in each country, who concluded upon a final version.  
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Questionnaires 
The original AddiQoL is a 36-item questionnaire; each item contains six scoring categories. Twenty-
five items are negative HRQoL statements that need to be reversed for questionnaire scoring; thus a 
higher score indicates a higher level of HRQoL. The questionnaire was developed in the English 
language, and initial statistic analysis performed in 85 patients form the UK (17). The SF-36 is a 
generic HRQoL questionnaire, widely used and thoroughly validated (28, 29). The SF-36 is translated 
into many languages, and has been used in previous studies of HRQoL in AD (11, 30). The PGWB is 
a validated 22-item generic HRQoL questionnaire that has been translated into several languages, 
intended to measure the subjective feeling of psychological well-being (31).  
 
Construct validity and Rasch analysis  
The Rasch model rests on the idea that useful measurement involves examination of only one human 
attribute at a time (unidimensionality), and that a higher score implies more of the measured concept. 
The model allows quantitative assessment (additivity of items) from data that are ordinal but not 
necessary linear, based on logistic transformation of the item responses (22). First, EFA was used to 
examine dimensionality of AddiQoL. Second, we applied Rasch analysis (RUMM 2020 software 
(32)), to further identify misfitting items, aiming for a unidimensional construct solution with fit to the 
Rasch model (33). The analysis gives overall fit statistics and estimates the individual items‟ and 
persons‟ fit to the model. 
 
Overall fit statistics include item-person interaction statistics, calculated as mean item location and 
mean person location. Both person fit and item fit is transformed by RUMM to approximate a Z-score; 
this represents a standardized Normal Distribution. Therefore, if the items and persons fit the model 
perfectly, the mean Fit Residual is expected to be zero with standard deviations around 1. Overall fit 
statistics also includes χ2 statistics for item-trait test-of-fit to the model. This tests whether the items 
work as expected at group level along the range of the scale. A non-significant χ2 probability implies 
that the hierarchical ordering of items and persons do not vary across the range of the scale.   
 
Individual item fit analysis identifies misfitting or biased items, thus producing information about how 
to optimize the item solution and refine the questionnaire. Generally, any item with a Fit Residual 
greater than +/- 2.5 is a cause of concern; a high positive item Fit Residual indicates that the item does 
not separate well between high and low person ability, and a high negative item Fit Residual indicates 
redundancy or local dependency (see below) of the item.  
 
Other causes for misfit to the Rasch model are disordered thresholds and differential item functioning 
(DIF, item bias). A threshold is the point where the probability of endorsing two neighboring response 
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alternatives is equal; one threshold exists for each transition between one scoring alternative to the 
next. To obtain ordered thresholds, each item and response alternative was assessed, and collapsed or 
rescored when necessary to improve fit. DIF analysis explores item performance and instrument 
performance across different patient groups. DIF exists if one patient group scores significantly 
different on an item compared with another patient group, given that the overall HRQoL level of the 
two groups is the same (21). Here, we performed DIF analysis for patient sex, age, concurrent disease, 
country and time point (for test-retest reliability analysis). 
 
Each item‟s difficulty (item location) and each person‟s ability (person location) are organized in 
ordered hierarchies (22, 34). By plotting item location and person location on the same scale the 
targeting of the items for the sample population can be explored. A perfect targeting is indicated if 
average person location is zero.  
  
To produce a psychometrically meaningful total score; the scale has to be unidimensional (22). This is 
tested by Principal Component analysis of the Fit Residuals. Fit to the model and an absence of a 
significant pattern among the Fit Residuals supports the scale being unidimensional, i.e. there is only 
one concept being measured. Local dependency exists when there is covariance between the response 
patterns of items, and this is considered a breach of the strict unidimensionality that the Rasch model 
requires. This can be corrected for by grouping items with covariance together, i.e. treating the item 
group mathematically as a single combined item (35). If fit to the model and unidimensionality are 
present, the individual Person location can then be used (directly or transformed to a total score) as a 
psychometrically valid total score for each patient, achieving an interval measure, as opposed to the 
ordinal raw scores.  
 
Reliability 
PSI is calculated as the ratio of adjusted (true) variance to observed variance and represents the 
proportion of variance that is not due to error (23, 34). A PSI of 0.85 is generally required if the scale 
is to be used on the individual level. For longitudinal reliability, a test-retest DIF analysis was 
performed for patient subgroups with stable clinical condition in Norway, Italy and Sweden, over two 
to six weeks‟ intervals. 
 
Concurrent validity and normative data 
AddiQoL scores were compared with SF-36 scores and PGWB score in Norway and Sweden. 
Spearman‟s rho with two-tailed significance was calculated for the correlation analysis. Mann-
Whitney U-test was used to compare Norwegian patients‟ AddiQoL scores with AddiQoL results from 
a random Norwegian population sample. Comparison of AddiQoL and Fatigue scores in different 
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subgroups of patients was performed by multiple linear regression analysis with sex, age, country and 
comorbidity as independent variables. 
 
 
Results 
 
Subjects 
A total of 615 patients were recruited from Norway (n=107), Italy (n=157), Germany (n=200), 
Sweden (n=101) and Poland (n=50). The Polish data were omitted from some of the analyses due to 
low number and lacking data. The original UK data were also included in the pooled data. Patient 
characteristics are presented in Table 1. Information on patient comorbidities was available for 
Norway, Italy, Germany and Sweden. Test-retests were available from patients in Norway (n=37), 
Italy (n=25) and Sweden (n=29). SF-36 and PGWB scorings were available from Norway (n=107) and 
Sweden (n=101). Of the 2000 Norwegians invited to participate in the study as a normative sample, 76 
invitations were returned unopened and 539 persons responded, producing a response rate of 28%. Of 
the respondents 54% (283) were female and 56% (300) were below the age of 50 (18-39, n=166; 40-
49, n=134; 50-59, n=123; >60, n=107).  
 
Translation and quality of questionnaire responses 
Overall, the evaluations from the professional translators were favorable; mostly minor errors were 
noted. Most of the suggestions from the translators were endorsed. The item “I feel lightheaded” 
proved difficult to translate. In Poland the clinicians did not endorse the suggestions from professional 
translators, as they believed that their version was more in keeping with everyday doctor-patient 
communication. Overall, the rate of missing responses was below 1%. There was a tendency towards 
missing responses on page 2 of the questionnaire, as a few patients did not complete page 2. Items 
regarding sexuality had the most missing responses, “I am satisfied with my sex-life” (item11) 7%, 
and “I have lost interest in sex” 4.9%. This was not evenly distributed among countries as 22% of 
patients in Poland did not report on item 11, whereas the result for Norway was 0.9% (UK 7%, Italy 
7.3%, Germany 5.5% and Sweden 6.9%).  
 
Construct validity 
Initial overall fit statistics of the 36-item questionnaire showed misfit to the Rasch model. EFA 
identified four sub-dimensions of AddiQoL, which we denoted Fatigue (8 items), Emotions (8 items), 
Symptoms (11 items) and Miscellaneous (sleep, sexuality and impact of intercurrent disease, 6 items) 
(see Supplementary Table 1 for item overview). The three items “nocturia”, “dry skin” and “gaining 
weight” did not belong to any sub-dimension by EFA, had high item fit residuals and poor 
discriminating properties in the Rasch analysis. Further Rasch analysis revealed that the Fatigue 
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domain fitted the Rasch model and achieved unidimensionality in all countries, and no significant DIF 
was present for sex, age or co-morbidity. The Emotions sub-dimension showed overall good fit to the 
Rasch model, but there was multidimensionality in the Norwegian data. The item “Emotional stress 
makes me exhausted” had high residual correlation with the item “I cope well in emotional situations” 
and displayed DIF in the Swedish data, hence the former item was discarded, improving fit. In the 
Symptoms sub-dimension the item “I have salt cravings” seems to have high clinical relevance but 
nevertheless displayed misfit in nearly all countries (Figure1a). Elimination of this item improved fit 
to the model, but χ2 probability remained significant in Italian and German data. The Miscellaneous 
sub-dimension showed overall good fit and unidimensionality, but the item “I have lost interest in sex” 
displayed DIF by sex in the Norwegian, Italian and German data, and DIF by age in the Italian and 
German data (Figure 1b). Removal of this item improved fit.  
 
Disordered thresholds were present for many items, indicating that the subjects had difficulties 
differentiating between some response alternatives. We found that rescoring the original six response 
alternatives (123456) to four (122334) by collapsing the scoring categories “a little of the time”/”some 
of the time”, “a good bit of the time”/”most of the time”, “agree”/”slightly agree” and 
“disagree”/”slightly disagree” improved fit and produced ordered thresholds. 
 
The 30 remaining items, rearranged in the four revised sub-dimensions as super-items, fitted the Rasch 
model; supported by a non-significant item-trait interaction (χ2=0.56) in the pooled data. Also, this 
item solution proved unidimensional. Table 2 displays the overall fit statistics for the pooled data and 
for individual countries. There was no significant DIF between genders, and no DIF when comparing 
results from patients with isolated AD with patients with autoimmune poly-endocrine syndromes. 
Significant DIF for age was present in the Emotions sub-dimension in the Swedish and the pooled 
data. Significant DIF for country was present in the Fatigue, the Symptom and the Miscellaneous sub-
dimensions. Based on these results we chose to go ahead with validation of the revised 30-item 
questionnaire (AddiQoL-30) and the Fatigue subscale.    
 
Targeting of the items to the total patient population is shown in Figure 2. Mean person location was 
0.21, indicating that mean patient score was slightly higher than the HRQoL level targeted by the 
mean of the items (set at zero). Mean person location for individual countries was -0.04 (Poland), 0.09 
(Germany), 0.14 (UK), 0.21 (Italy), 0.23 (Norway) and 0.27 (Sweden), indicating good targeting in all 
countries.  
 
Reliability 
AddiQol-30 demonstrated good reliability as indicated by Cronbach‟s α 0.93 and PSI 0.86. PSIs for 
individual countries are presented in Table 2. For the Fatigue sub-dimension PSI ranged from 0.89 to 
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0.91 in individual countries, indicating excellent reliability as a separate scale. A total of 91 clinically 
stable patients from Norway, Sweden and Italy performed test-retest 2-6 weeks after the first 
evaluation. Longitudinal reliability was excellent, as no significant DIF between separate time points 
was detected. 
 
Concurrent validity, patient scores and normative data 
Rasch-transformed AddiQoL-30 and Fatigue scores were compared with SF-36 scores and PGWB 
scores in Norwegian (n=107) and Swedish (n=101) patients. Results from the correlation analyses are 
given in Table 3. AddiQoL raw scores in patients (median 89, n= 99) were significantly lower than in 
controls in Norway (Median 97, n = 462; U = 14799, z = -5.516, p <0.001, r = 0.23), shown for 
individual age groups and sex in Figure 3. Rasch transformed scores from all countries are shown in 
Figure 4. Regression analysis adjusting for age, sex, country and comorbidity showed that women 
scored significantly worse than men (AddiQoL-30 p <0.001; Fatigue p= 0.001) and demonstrated 
worse scores with increasing age (AddiQoL-30 p<0,001; Fatigue p= 0.001),as indicated for 
Norwegian data in Figure 4. No statistical difference was found between patients with isolated AD and 
those with autoimmune polyendocrine syndromes.  
 
Discussion 
The validation process concluded with a revised 30-item AddiQoL questionnaire. High reliability, here 
demonstrated by adequate PSI and a high Cronbach‟s α, indicates that the items discriminate well 
between groups of patients with different HRQoL levels. High reliability and good discriminative 
properties will usually imply good evaluative properties. On the other hand, a too high reliability 
coefficient is not necessarily desirable, as the same properties that increase the reliability coefficients 
might reduce ability to detect change (responsiveness) (36).  
 
The final revised AddiQoL-30 fitted the stringent Rasch model, which implies that basic requirements 
for a measurement instrument such as unidimensionality, order, and additivity are fulfilled. 
This solution had the best fit to the Rasch model, proved unidimensional and had the best targeting to 
the patient sample.The Fatigue sub-dimension alone had good psychometric properties, and a higher 
reliability than AddiQoL-30, and was therefore kept as a separate index for further validation. 
However, the Fatigue scale did not target the whole patient population as well as AddiQoL-30, 
yielding risk of floor- and ceiling effects that might compromise responsiveness. 
 
One important validity aspect is whether individual items work similarly in different patient 
subgroups, that is, whether item bias exists (37). No significant DIF was found between patients with 
isolated AD and patients with autoimmune polyendocrine syndromes, and no DIF by sex remained in 
AddiQol-30, indicating equal performance regardless of comorbidities and sex. Thus reassured that 
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AddiQoL-30 performs equally in these patient groups, the significantly lower total scores in females 
than males represent a true difference. Similarly, no significant difference in AddiQol-30 scores 
between patients with isolated AD and those with polyendocrine syndromes is reliable. Both findings 
are consistent with earlier studies applying SF-36 in AD (11, 14). We cannot rule out that the 
demonstrated DIF by country is due to qualitative differences of the translations. If the aim were to 
study HRQoL differences between countries, statistical adjustment is required for items with DIF 
country (38). However, DIF country may have negligible clinical impact on the HRQoL results from a 
clinical trial (39).           
 
We demonstrate high correlation between the AddiQoL-30 score and SF-36 and PGWB. For SF-36 
the correlation was highest with the vitality and general health scales, which were also most affected in 
previous studies in AD (3, 11, 14, 30). Normative data are not essential in the validation of a disease-
specific questionnaire, since several of the issues may not be relevant to healthy subjects. Normative 
data were only collected from Norway; the response rate was low, which could imply selection bias, 
but age and sex distribution resembled that of the patient group. We found a statistically significant 
difference between the patients and the controls, but the effect size was small. Several of the items 
showed ceiling effects in the controls, which underestimates the effect size. Furthermore, comparison 
of patients with healthy controls always implies some response bias or a response shift due to 
adaptation to chronic diseases (40).   
 
The results of the Rasch analysis suggest a revised scoring algorithm. The analysis revealed that the 
six response categories of each item had to be collapsed into four to obtain order, additivity, and fit to 
the model. The unidimensional structure of the rescored AddiQol-30 suggests that an index based on 
the algebraic sum of the item (after reversal of negative items) scores will be valid for practical 
purposes, for instance in cross-sectional studies. AddiQoL was however primarily developed as an 
evaluative instrument of within-individual measurement in clinical trials. For this purpose Rasch 
transformed person location scores will be the optimal psychometric solution. AddiQoL-30 could 
possibly be further shortened to reduce the respondents‟ burden. However, the items most sensitive to 
change might not be the most well-fitting items (36, 41), hence further item reduction will be re-
evaluated after testing for responsiveness. The Fatigue sub-dimension displayed optimal overall fit 
statistics and could be useful as a separate AddiQoL short version.  
  
In conclusion, the validation process concluded with a revised 30-item AddiQoL questionnaire and a 
Fatigue subscale that have high internal consistency and reliability. Its validity as a HRQoL instrument 
in AD was further substantiated by high correlation with SF-36 subscales and the PGWB Index. 
Although further studies are necessary to examine its responsiveness to changes in HRQoL over time, 
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this study suggests that the AddiQoL could become a valuable tool in the assessment of subjective 
health status in patients with Addison‟s disease. 
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Figure legends 
 
Figure 1 a. Fit to the Rasch model for the item “I have salt cravings”. The grey line depicts the 
expected scoring pattern as estimated by the model. The black dots are actual scoring from groups of 
patients with similar HRQoL levels (class intervals). The patients with the highest HRQoL level 
(far right) scores less than expected, the patients with the lowest HRQoL level (far left) scores better 
than expected; i.e. this item does not separate  well between high and low HRQoL. b. DIF sex for the 
item “I have lost interest in sex”. The grey line depicts the expected scoring pattern estimated from the 
Rasch model. Men score better than expected, females worse; p<0.01. This item showed similar 
results for DIF age. Patients below 50 years scored worse than expected, patients above 50 years better 
than expected; p<0.01.  
 
Figure 2. Person-item targeting for the revised 30-item AddiQoL. The upper half of the figure 
displays spread in AddiQoL scores (person location) for all patients. The lower half depicts item 
threshold distribution (item location). The item thresholds cover the range of HRQoL scores obtained 
by the patients, hereby minimizing the risk of floor- and ceiling effects.  
 
Figure 3. AddiQoL-30 raw scores (range 30-120) in Norwegian patients (grey) and controls (black), 
in males (a) and females (b). Fatigue raw scores (range 8-32) in patients (grey) and controls (black) in 
males (c) and females (d). Error bars represent 95% CI. 
 
Figure 4 a. Rasch-transformed AddiQoL-30 scores (range 0-100); and b.Rasch-transformed Fatigue 
scores (range 0-25); for each country; males gray, females white; median and interquartile range 
(boxes). 
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Table1. Patient characteristics 
   Norway  Italy*  Germany  Sweden  Poland** 
   (n=107)  (n=157)  (n=200)  (n=101)  (n=50) 
            
Sex Male (%)  39 (36.4)  54 (34.8)  53 (26.5)  36 (35.6)  10 (20) 
 Female (%)  68 (63.6)  101 (65.2)  147 (73.5)  65 (64.4)  40 (80) 
            
Age 18-29 (%)  6 (5.6)  16 (10.5)  15 (7.5)  6 (5.9)  NA 
 30-39 (%)  17 (15.9)  42 (27.5)  35 (17.5)  18 (17.8)  NA 
 40-49 (%)  29 (27.1)  43 (28.1)  58 (29.0)  22 (21.8)  NA 
 50-59 (%)  32 (29.9)  27 (17.6)  42 (2.0)  27 (26.7)  NA 
 60-69 (%)  22 (20.6)  17 (11.1)  29 (14.5)  17 (16.8)  NA 
 > 70 (%)  1 (0.9)  8 (5.2)  21 (10.5)  11 (10.9)  NA 
            
Comorbidity 
(autoimmune) 
Present (%)  70 (65.4)  106 (68.4)  153 (76.5)  60 (59.4)  NA 
 None (%)  37 (36.4)  46 (29.7)  47 (23.5)  41 (40.6)  NA 
 Thyroid 
disease (%) 
 55 (50.9)  83 (52.5)  125 (62.5)  45 (44.6)  NA 
 Type 1 
diabetes (%) 
 13 (12.0)  6 (3.8)  20 (10)  9 (8.9)  NA 
 Other***(%)  33 (30.6)  21 (13.4)  62 (31)  25 (24.8)  NA 
 
* Italy: 16 patients were classified as APS2, these are included in comorbidities, but excluded from the thyroid 
and diabetes numbers. **Data regarding age and comorbidity are missing from Poland, and from a few Italian 
patients (sex, n=2); age (n=4) and comorbidities (n=2). ***Includes coeliac disease, hypoparathyroid disease, 
pernicious anemia, primary ovarian failure. NA; not available. 
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Table2. Overall fit to the Rasch model; the AddiQoL-30 results  
   Norway  Sweden  Italy  Germany  Poland  All countries 
   (n=107)  (n=101)  (n=156)  (n=200)  (n=50)  (n=696) 
              
Item Fit Residual (SD)  -0.55 (1.15)  -0.57 (1.45)  -0.51 (0.90)  0.01 (1.48)  -0.47 (0.9)  0.00 (2.7) 
Person Fit Residual (SD)  -0.52 (1.06)  -0.62 (1.22)  -0.6 (1.08)  -0.48 (1.13)  -0.66 (1.2)  -0.51 (1.15) 
χ2 probability  0.81  0.66  0.88  0.73  0.92  0.73 
Person Separation Index  0.84  0.87  0.83  0.91  0.85  0.86 
Cronbach‟s α  ND  ND  ND  ND  ND  0.93 
             
All countries also includes original UK data (n=82). Item Fit Residual: Mean item deviation from model estimations. Person Fit Residual: 
Mean person deviation from model estimations. A non-significant χ2 probability implies that the hierarchical ordering of 
 items and persons do not vary across the range of the scale. ND; not done.   
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Table3. Concurrent validity; correlation between AddiQoL30 scores and Fatigue scores with SF-36 
and PGWB scores.  
  Norway (n=107) Sweden (n=101) 
  AddiQoL30 Fatigue AddiQoL30 Fatigue 
SF-36 Physical functioning 0.743 0.745 0.692 0.687 
Role Physical 0.689 0.729 0.717 0.661 
Bodily Pain 0.604 0.538 0.637 0.545 
General Health 0.802 0.775 0.768 0.692 
Vitality 0.753 0.748 0.837 0.803 
Social Functioning 0.685 0.676 0.603 0.585 
Role Emotional 0.433 0.418 0.466 0.411 
Mental Health 0.585 0.554 0.724 0.675 
PGWB Total score 0.816 0.797 0.785 0.706 
Spearman‟s rho; All correlations were significant below the 0.01 level (two-tailed). SF-36; Short 
Form-36. PGWB; Psychological General Well-Being Index. 
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Supplementary Table1: AddiQoL items 
Fatigue sub-dimension: 
  1. I feel good about my health 
  2. I can keep going during the day without feeling tired 
  3. Normal daily activities make me tired 
  4. I have to struggle to finish jobs 
  5. I have to push myself to do things 
25. My ability to work is limited 
28. I feel full of energy 
29. I feel physically fit 
Emotions sub-dimension: 
12. I am relaxed 
13. I feel low or depressed 
14. I am irritable 
15. I find it difficult to think clearly 
26. I can concentrate well 
27. I am happy 
36. I cope well in emotional situations 
Symptoms sub-dimension: 
  6. I lose track of what I want to say 
10. I feel unwell first thing in the morning 
16. I feel lightheaded 
18. I sweat for no particular reason 
19. I get headaches 
20. I get nauseous 
21. My joints and/or muscles ache 
22. I have back pain 
23. My legs feel weak 
24. I worry about my health 
Miscelleneous sub-dimension: 
  7. I sleep well 
  8. I feel rested when I wake up in the morning 
11. I am satisfied with my sex life 
34. I get ill more easily than others 
35. I take a long time to recover from illnesses 
Discarded items: 
  9. I need to get up during the night to pass water 
17. I have salt cravings 
30. Emotional stress makes me exhausted 
31. I have lost interest in sex 
32. I put on weight easily 
33. I have dry skin 
 
 
 
 
 
 
